Clin Gastroenterology H: The risk of liver cancer can be reduced by anti-fibrosis therapy in patients with hemoglobinia caused by HFE mutations.

The risk of liver fibrosis in patients with hemoglobinal conditioning disorders in the background and target of the stable iron regulatory gene (HFE) mutation is greatly increased, and this study aims to assess whether the risk of liver cancer is reduced after treatment with anti-fibrosis.
method researchers reviewed 106 cases of ChPE mutations in France and Australia that were purely f3 fibrosis (n s 40) or F4 fibrosis (n s 66) and performed at least one liver biopsy.
median time between the first and last liver biopsy was 9.5 years (range 3.5-15.6 years).
also collected test results for liver function, iron storage markers and platelet levels.
results In the last liver biopsy, 41 patients (38.6%) had a fibrosis score of F2 or lower.
34 cases of liver cancer (52.3%) in patients with F3 or F4 fibrosis at the last liver biopsy, compared with 2 cases of F2 or less in the most recent liver biopsy (4.8%) (P.lt;001). The incidence of liver cancer in
F3 or F4 fibrosis patients is 32.8 (95% CI, 22 per 1,000 people per year) per thousand people. 7-45.9) and 2.3 per thousand people (95% CI, 0.2-8.6 years per thousand population).
in multivariate analysis, males (risk ratio, 6.09; 95% CI, 1.21-30.4), age at the time of diagnosis (HR, 1.16; 95% CI, 1.09-1.25), diabetes (HR, 3.07; 95) %CI, 1.35-6.97), excessive alcohol consumption (HR, 3.1; 95% CI, 1.47-6.35) are independent risk factors for liver cancer.
conclusions in a retrospective analysis of hemoglobinal resepneal patients caused by the C282Y mutation in HFE, the researchers found that severe liver fibrosis can be treated to subside.
significantly reduced long-term risk of liver cancer in patients whose fibrosis subsides to F2 or below.
.